VolitionRx Limited Overview
Pro stress-test →VolitionRx Limited is a multi-national epigenetics company that develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company utilizes proprietary nucleosomics technology to create non-invasive diagnostic solutions that aim to provide early disease detection.
Strategic Profile
Pro stress-test →2025 is a pivotal year for Volition as it focuses on commercializing its Nu.Q® platform in the human diagnostics market, with confidential discussions with more than ten companies, where the combined market value of seven of these companies exceeds $600 billion. The company's business model is based on a dual-path strategy: developing high-impact diagnostic tests for both human and animal health, and monetizing its intellectual property through strategic licensing or collaboration deals with key industry partners.
Competitive Landscape
Pro stress-test →Volition has initiated commercial discussions with significant players in the diagnostic space for both human and animal health out-licensing opportunities in large markets such as sepsis and oncology liquid biopsy. Primary competitors in the blood-based cancer diagnostics space include Guardant Health, Foundation Medicine, and other liquid biopsy developers, though Volition's nucleosomics approach and dual-market strategy (human and veterinary) provide differentiation.
Industry Context
VolitionRx Limited operates in Diagnostic Medical Devices & Epigenetics Biotech.
Key facts
Headquarters: Henderson, Nevada, United States · Employees: 85 · Revenue: $0.25M (Q1 2025)